Skip to main content
LIGAND PHARMACEUTICALS INC logo

LIGAND PHARMACEUTICALS INC — Investor Relations & Filings

Ticker · LGND ISIN · US53220K5048 LEI · 5493008K7TB0IKP37H79 US Financial and insurance activities
Open in API
Filings indexed 1,392 across all filing types
Latest filing 2013-06-04 Director's Dealing
Country US United States of America
Listing US LGND

About LIGAND PHARMACEUTICALS INC

https://www.ligand.com/

Ligand Pharmaceuticals Incorporated is a biopharmaceutical company that functions as a capital and technology partner to the life sciences industry. The company's business model focuses on acquiring and developing royalty-generating assets by investing in the clinical development and commercialization of medicines. It manages a large, diverse portfolio of economic rights to partnered programs across therapeutic areas such as oncology, kidney disease, diabetes, and rare conditions. In addition to its royalty business, Ligand develops and licenses its proprietary technology platforms to a global network of biopharmaceutical partners. Its key technologies include Captisol®, a chemically modified cyclodextrin used to improve the solubility and stability of active pharmaceutical ingredients, and the NITRICIL™ platform.

Recent filings

Filing Released Lang Actions
4 Filing
Director's Dealing
2013-06-04 English
8-K Filing
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content describes the termination of a material definitive agreement related to a research license and option agreement. There are no financial statements or detailed financial data presented, nor is this an announcement of an annual or quarterly report. The document is not a certification or a proxy statement, nor does it relate to management changes, voting results, or capital changes. It is a regulatory announcement about a contract termination event. Given the nature of the Form 8-K and the content, this fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2013-05-20 English
4 Filing
Director's Dealing
2013-05-13 English
10-Q Filing
Interim / Quarterly Report Q1 2013
2013-05-08 English
8-K Filing
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The text mentions the announcement of quarterly financial results for the quarter ended March 31, 2013, and financial guidance for the next quarter, both provided via a press release (Exhibit 99.1). It also announces a share repurchase program authorized by the Board of Directors. The document explicitly states that the press release is furnished as an exhibit and is incorporated by reference, indicating that the actual financial results are in the press release, not fully contained in this filing. The Form 8-K is primarily an announcement of these events rather than the full earnings release itself. However, the content corresponds to an Earnings Release event (initial announcement of quarterly financial results and guidance). The share repurchase program announcement also aligns with Capital/Financing Update, but the primary focus is on the earnings announcement. Given the nature of Form 8-K and the inclusion of the press release announcing quarterly results, the best classification is Earnings Release (ER). Confidence is high because the document clearly states it is announcing quarterly financial results and guidance via a press release on the same date, which is typical for an Earnings Release filing.
2013-05-08 English
8-K Filing
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The text specifically describes the entry into a material definitive agreement involving a royalty stream and milestone payments purchase agreement. This type of disclosure fits the category of Capital/Financing Update (CAP) because it involves a significant financial transaction and agreement affecting the company's capital or financial arrangements. The document is short (2666 characters) and contains substantive information about the transaction, not just an announcement of a report or certification. Therefore, it is not a report publication announcement or regulatory filing. Hence, the correct classification is CAP with high confidence.
2013-04-30 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.